# ARS Pharmaceuticals (SPRY) — Earnings

SPRY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/spry/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.63 |
| EPS estimate | −$0.48 |
| EPS surprise | −31.88% |
| Revenue surprise | +7.46% |
| Revenue | $33.7M |
| Revenue estimate | $31.3M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1671858/000119312526349140/spry-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/cddf05bb-9d75-420f-f6d5-c06abd528a70.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | −$0.48 | −$0.63 | -31.88% | $31.3M | $33.7M |
| Q1 2026 | May 15, 2026 | −$0.52 | −$0.61 | -18.22% | $22.2M | $22.7M |
| Q4 2025 | Mar 9, 2026 | −$0.43 | −$0.41 | 4.63% | $25.6M | $28.1M |
| Q3 2025 | Nov 10, 2025 | −$0.45 | −$0.52 | -14.59% | $28.7M | $32.5M |
| Q2 2025 | Aug 13, 2025 | −$0.46 | −$0.46 | -0.41% | $13.8M | $15.7M |
| Q1 2025 | May 14, 2025 | −$0.34 | −$0.35 | -3.46% | $7.5M | $8.0M |
| Q4 2024 | Mar 20, 2025 | −$0.24 | $0.48 | 302.11% | $5.7M | $86.6M |
| Q3 2024 | Nov 13, 2024 | −$0.14 | −$0.20 | -40.35% | $575,000.00 | $2.1M |
| Q2 2024 | Aug 6, 2024 | −$0.11 | −$0.13 | -17.54% | $1.0M | $500,000.00 |
| Q1 2024 | May 9, 2024 | −$0.10 | −$0.11 | -11.22% | — | — |
| Q4 2023 | Mar 21, 2024 | −$0.14 | −$0.07 | 49.05% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.18 | −$0.16 | 10.01% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.17 | −$0.18 | -7.98% | — | $10,000.00 |
| Q1 2023 | May 15, 2023 | −$0.16 | −$0.16 | -2.11% | — | $20,000.00 |
| Q4 2022 | Mar 23, 2023 | −$0.13 | −$0.26 | -103.76% | $94,500.00 | $650,000.00 |
| Q3 2022 | Nov 2, 2022 | −$0.50 | −$0.50 | 0.00% | — | — |
| Q1 2022 | May 12, 2022 | −$0.50 | −$0.70 | -41.41% | — | — |
| Q4 2021 | Mar 31, 2022 | −$0.67 | −$0.67 | 0.59% | — | — |
| Q3 2021 | Nov 10, 2021 | −$0.65 | −$0.65 | 0.31% | — | — |
| Q2 2021 | Aug 12, 2021 | −$0.54 | −$0.70 | -30.60% | — | — |

## Frequently Asked Questions

### When did ARS Pharmaceuticals (SPRY) last report earnings?

ARS Pharmaceuticals last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did SPRY beat earnings estimates?

No. ARS Pharmaceuticals reported EPS of −$0.63 for Q2 2026 against a −$0.48 estimate — a 31.88% miss.

### How much revenue did SPRY report last quarter?

ARS Pharmaceuticals reported $33.7M in revenue for Q2 2026, against a consensus estimate of $31.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).